Clinical Trial

Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

Unknown
View on ClinicalTrials.gov →
Summary
To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT03614689
Lead Sponsor Geneplus-Beijing Co. Ltd.
Collaborators: Peking Union Medical College Hospital
Conditions Ovarian Cancer
Enrollment 104 participants
Start Date 2017-11-25
Primary Completion 2020-11-30 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-07-18